Skip to main content
NASDAQ:AQXP

Aquinox Pharmaceuticals Stock Forecast, Price & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
$11.40
+0.66 (+6.15 %)
(As of 05/11/2021 12:00 AM ET)
Add
Compare
Today's Range
$10.35
▼
$11.73
50-Day Range
$3.68
▼
$4.03
52-Week Range
$2.00
▼
$3.84
Volume137,386 shs
Average Volume239,362 shs
Market Capitalization$268.36 million
P/E RatioN/A
Dividend YieldN/A
Beta-7.37

Receive AQXP News and Ratings via Email

Sign-up to receive the latest news and ratings for Aquinox Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.


Aquinox Pharmaceuticals logo

About Aquinox Pharmaceuticals

Aquinox Pharmaceuticals, Inc., a clinical stage pharmaceutical company, engages in developing novel therapeutics for chronic urological conditions by inflammation and pain. The company focuses on a library of novel compounds that activate SH2-containing inositol-5'-phosphatase 1 (SHIP1) to develop therapeutics for application in inflammation, inflammatory pain, and blood cancers. Its lead product candidate is Rosiptor (Leadership 301), a small molecule activator of SHIP1 that is in Phase III clinical trials for treatment in interstitial cystitis/bladder pain syndrome. The company was formerly known as Aquinox Pharmaceuticals (USA) Inc. and changed its name to Aquinox Pharmaceuticals, Inc. in January 2014. Aquinox Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Vancouver, Canada.

Headlines

Sun Pharma to acquire Canada-based Aquinox Pharmaceuticals for 8.2 mn
Sun Pharma to acquire Canada-based Aquinox Pharmaceuticals for 8.2 mn
July 29, 2020 |  www.msn.com
Analyzing the Financial Health of Biotech Companies
Analyzing the Financial Health of Biotech Companies
May 23, 2020 |  www.bloomberg.com
Edited Transcript of AQXP earnings conference call or presentation 12-Mar-20 8:30pm GMT
Edited Transcript of AQXP earnings conference call or presentation 12-Mar-20 8:30pm GMT
March 13, 2020 |  finance.yahoo.com
Neoleukin Therapeutics and Aquinox Pharmaceuticals Complete Merger Transaction
Neoleukin Therapeutics and Aquinox Pharmaceuticals Complete Merger Transaction
August 9, 2019 |  finance.yahoo.com
UW spinout Neoleukin Therapeutics goes public in acquisition
UW spinout Neoleukin Therapeutics goes public in acquisition
August 8, 2019 |  finance.yahoo.com
Neoleukin Therapeutics to Present at Canaccord Genuity 39th Annual Growth Conference
Neoleukin Therapeutics to Present at Canaccord Genuity 39th Annual Growth Conference
August 7, 2019 |  finance.yahoo.com
BRIEF-Aquinox Pharmaceuticals And Neoleukin Therapeutics Announce Merger Agreement
BRIEF-Aquinox Pharmaceuticals And Neoleukin Therapeutics Announce Merger Agreement
August 6, 2019 |  www.msn.com
Aguinox Pharma down 15% on merger with Neoleukin
Aguinox Pharma down 15% on merger with Neoleukin
August 6, 2019 |  seekingalpha.com
Aquinox Pharmaceuticals and Neoleukin Therapeutics announce merger agreement
Aquinox Pharmaceuticals and Neoleukin Therapeutics announce merger agreement
August 6, 2019 |  finance.yahoo.com
Imagine Owning Aquinox Pharmaceuticals (NASDAQ:AQXP) While The Price Tanked 68%
Imagine Owning Aquinox Pharmaceuticals (NASDAQ:AQXP) While The Price Tanked 68%
July 27, 2019 |  finance.yahoo.com
See More Headlines

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:AQXP
Previous Symbol
CUSIPN/A
CIK1404644
Webwww.aqxpharma.com
Phone604-629-9223
Employees8
Year FoundedN/A

Sales & Book Value

Annual Sales$25 million
Price / Sales10.73
Cash FlowN/A
Price / Cash FlowN/A
Book Value$3.09 per share
Price / Book3.69

Profitability

EPS (Most Recent Fiscal Year)N/A
Net Income$-31,580,000.00
Net MarginsN/A
Return on Equity-30.13%
Return on Assets-28.08%

Debt

Debt-to-Equity RatioN/A
Current Ratio63.17
Quick Ratio63.17

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Miscellaneous

Outstanding Shares23,540,000
Market Cap$268.36 million
Next Earnings DateN/A
OptionableOptionable

MarketRank™

Overall MarketRank™

0.89 out of 5 stars

Medical Sector

1154th out of 2,042 stocks

Pharmaceutical Preparations Industry

506th out of 770 stocks

Analyst Opinion: 0.0Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











Aquinox Pharmaceuticals (NASDAQ:AQXP) Frequently Asked Questions

What stocks does MarketBeat like better than Aquinox Pharmaceuticals?

Wall Street analysts have given Aquinox Pharmaceuticals a "N/A" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Aquinox Pharmaceuticals wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

How were Aquinox Pharmaceuticals' earnings last quarter?

Aquinox Pharmaceuticals Inc (NASDAQ:AQXP) issued its quarterly earnings results on Thursday, November, 8th. The company reported ($0.64) earnings per share for the quarter, missing analysts' consensus estimates of ($0.21) by $0.43.
View Aquinox Pharmaceuticals' earnings history.

Who are Aquinox Pharmaceuticals' key executives?

Aquinox Pharmaceuticals' management team includes the following people:
  • Mr. David J. Main, Co-Founder, Chairman, CEO & Pres (Age 54)
  • Mr. Kamran Alam, CFO, VP of Fin. & Corp. Sec. (Age 45)
  • Ms. Shelley McCloskey, VP of HR & Admin. (Age 59)

Who are some of Aquinox Pharmaceuticals' key competitors?

Some companies that are related to Aquinox Pharmaceuticals include DiaMedica Therapeutics (DMCAF), Rhythm Pharmaceuticals (RYTM), Phibro Animal Health (PAHC), Zogenix (ZGNX), Enanta Pharmaceuticals (ENTA), Kiniksa Pharmaceuticals (KNSA), Mersana Therapeutics (MRSN), MannKind (MNKD), Humanigen (HGEN), Vanda Pharmaceuticals (VNDA), Radius Health (RDUS), Olema Pharmaceuticals (OLMA), Constellation Pharmaceuticals (CNST), Akero Therapeutics (AKRO) and ESSA Pharma (EPIX).
View all of AQXP's competitors.

What other stocks do shareholders of Aquinox Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Aquinox Pharmaceuticals investors own include Novavax (NVAX), Bausch Health Companies (BHC), Sarepta Therapeutics (SRPT), ACADIA Pharmaceuticals (ACAD), Gilead Sciences (GILD), XOMA (XOMA), Alnylam Pharmaceuticals (ALNY), Inovio Pharmaceuticals (INO), SodaStream International (SODA) and ZIOPHARM Oncology (ZIOP).

What is Aquinox Pharmaceuticals' stock symbol?

Aquinox Pharmaceuticals trades on the NASDAQ under the ticker symbol "AQXP."

What is Aquinox Pharmaceuticals' stock price today?

One share of AQXP stock can currently be purchased for approximately $11.40.

How much money does Aquinox Pharmaceuticals make?

Aquinox Pharmaceuticals has a market capitalization of $268.36 million and generates $25 million in revenue each year.

How many employees does Aquinox Pharmaceuticals have?

Aquinox Pharmaceuticals employs 8 workers across the globe.

What is Aquinox Pharmaceuticals' official website?

The official website for Aquinox Pharmaceuticals is www.aqxpharma.com.

Where are Aquinox Pharmaceuticals' headquarters?

Aquinox Pharmaceuticals is headquartered at 450-887 GREAT NORTHERN WAY, VANCOUVER A1, V5T 4T5.

How can I contact Aquinox Pharmaceuticals?

Aquinox Pharmaceuticals' mailing address is 450-887 GREAT NORTHERN WAY, VANCOUVER A1, V5T 4T5. The company can be reached via phone at 604-629-9223 or via email at [email protected]


This page was last updated on 5/13/2021 by MarketBeat.com Staff

As Featured By:

MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.